Can anyone tell me the original SRPT approval was on how many patients - was it 12? | SRPT Message Board Posts

Sarepta Therapeutics Inc.

  SRPT website

SRPT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  14215 of 14237  at  7/1/2020 2:08:55 PM  by

pineappleguava


 In response to msg 14213 by  Rob Cos
view thread

Re: Can anyone tell me the original SRPT approval was on how many patients - was it 12?

 This is an abstract from a 2014 AAN meeting that shares some stats through 96 weeks.
 
 Results at 96 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne Muscular Dystrophy (DMD)

Edward Kaye,1Jerry Mendell,2Louise Rodino-Klapac,2Zarife Sahenk,2Kandice Roush,2,2Loren Bird,2Linda Lowes,2,2Lindsay Alfano,2,2Ana Maria Gomez Ramirez,2Sarah Lewis,2,2Vinod Malik,2Kim Shontz,2,2Christopher Shilling,2,2Peter Sazani,1Jihad B. Saoud1

1Cambridge, MA, USA, 2Columbus, OH, USA

OBJECTIVE: The objective of this study is to establish long-term efficacy of eteplirsen treatment, targeted to skip exon 51.

BACKGROUND: DMD is a rare, degenerative, genetic disease that results in progressive muscle loss and premature death. Affecting 1 in 5000 male births, DMD is caused by the inability to produce the dystrophin protein. There are no approved drugs available to treat DMD. Eteplirsen is an investigational therapy designed to enable functional dystrophin production in boys who are amenable to exon 51-skipping therapy (~13%).

DESIGN/METHODS: Twelve boys aged 7-13 years with eligible genotypes were randomized 1:1:1 to 30 mg/kg, 50 mg/kg, or placebo. Upon completion of a 24-week double-blind, placebo-controlled study phase, all subjects were enrolled in an open-label extension and the placebo-treated subjects initiated eteplirsen treatment. The critical clinical endpoint was the change in 6-minute walk test (6MWT) distance from baseline compared to the placebo/delayed-treatment cohort.

RESULTS: After 96 weeks of treatment, a significant clinical benefit of 71 meters was observed (p≤0.001) on the 6MWT for ambulatory-evaluable subjects in the combined eteplirsen-treated cohorts (n=6) versus the placebo/delayed-treatment cohort (n=4). The eteplirsen-treated cohorts showed approximately 5% decline (19.3 meters) in walking ability from baseline. No clinically significant treatment-related adverse events were seen through 96 weeks.

CONCLUSIONS: Through 96 weeks of treatment, eteplirsen demonstrated a significant clinical benefit on the 6MWT with no clinically significant treatment-related adverse events. Data on these outcomes will be reported through 164 weeks of treatment.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 90
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...